ERBB2 and neoplasm: However, using positive immunomagnetic selection targeting EpCAM, HER2, and EGFR improved and optimized the enrichment of tumor stem cell and EMT like CTC compared to cell capturing with anti-EpCAM alone in different tumor entities (66–68).